Onconetix (ONCO) Non-Current Debt (2022 - 2026)
Onconetix (ONCO) posted quarterly Non-Current Debt of $200000.0 for Q1 2026, down 60.0% year-over-year from $500000.0 in Q1 2025, and down 96.0% quarter-over-quarter from $5.0 million in Q4 2025.
Onconetix (ONCO) Non-Current Debt (2022 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Non-Current Debt for 5 consecutive years, with $200000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 60.0% year-over-year to $200000.0; the TTM figure through Mar 2026 stood at $200000.0 (down 60.0% YoY), while the FY2025 annual figure was $5.0 million, changed 0.0% from the prior year.
- Non-Current Debt slipped to $200000.0 in Q1 2026 per ONCO's latest filing, from $5.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $5.0 million in Q1 2024 and bottomed at $111260.0 in Q2 2024.
- Historically, Non-Current Debt has averaged $1.4 million across 5 years, with a median of $462518.0 in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Debt surged 4106.74% — and 2025, when it tumbled 90.0%.
- Onconetix's Non-Current Debt stood at $569907.0 in 2022, then plunged by 79.14% to $118857.0 in 2023, then soared by 4106.74% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025, then plunged by 96.0% to $200000.0 in 2026.
- Business Quant data shows ONCO's Non-Current Debt at $200000.0 in Q1 2026, $5.0 million in Q4 2025, and $113725.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 150,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 150,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | 113,725.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 118,450.00 |
| Jun 30, 2024 | 111,260.00 |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | 118,857.00 |
| Sep 30, 2023 | 569,907.00 |
| Jun 30, 2023 | 462,518.00 |
| Dec 31, 2022 | 569,907.00 |